CN Patent

CN112707892A — 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物

Assigned to Shanghai Zejing Pharmaceutical Technology Co ltd · Expires 2021-04-27 · 5y expired

What this patent protects

本发明涉及哒嗪酮或哒嗪类化合物及其衍生物和药物组合物。具体地，本发明提供一种式(I)或(Ia)所示的哒嗪酮或哒嗪类化合物或其立体异构体、互变异构体、对映异构体、非对映异构体、共振体、其药学上可接受的盐、水合物、溶剂合物、或晶型。本发明所述的式(I)或(Ia)化合物对甲状腺激素β受体具有优异的激动作用和药效学性能。

USPTO Abstract

本发明涉及哒嗪酮或哒嗪类化合物及其衍生物和药物组合物。具体地，本发明提供一种式(I)或(Ia)所示的哒嗪酮或哒嗪类化合物或其立体异构体、互变异构体、对映异构体、非对映异构体、共振体、其药学上可接受的盐、水合物、溶剂合物、或晶型。本发明所述的式(I)或(Ia)化合物对甲状腺激素β受体具有优异的激动作用和药效学性能。

Drugs covered by this patent

resmetirom (RESMETIROM)

Patent Metadata

Patent number: CN112707892A
Jurisdiction: CN
Classification: —
Expires: 2021-04-27
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Zejing Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.